[18F]Fluciclatide PET Imaging of Pazopanib Response
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Positron emission tomography (PET) is a non-invasive imaging tool for monitoring functional
and metabolic responses of biological events with specific radiotracer in vivo. The PET
tracer [18F]Fluciclatide is an 18F radiolabeled small peptide containing the RGD
(arginine-glycine-aspartate) tri-peptide, which preferentially binds with high affinity to
αvβ3 and αvβ5 integrins. αvβ3-integrins are expressed at low levels on epithelial cells and
mature endothelial cells but are expressed at high levels on activated endothelial cells in
the neo-vasculature of a range of tumors and it also may regulate angiogenesis. If pazopanib
acts mainly on active angiogenetic tumors, the quantitative uptake of [18F]Fluciclatide can
be used to predict the effect of this antiangiogenic drug. The investigators expected the
baseline tumor uptake in [18F]Fluciclatide to be able to predict treatment response, and
planned a study of [18F]FluciclatidePET for patients with metastatic RCC who received
pazopanib systemic therapy.